# L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

> **NCT02891837** · PHASE3 · COMPLETED · sponsor: **Asklepion Pharmaceuticals, LLC** · enrollment: 189 (actual)

## Conditions studied

- Acute Lung Injury

## Interventions

- **DRUG:** L-citrulline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02891837
- **Lead sponsor:** Asklepion Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-06
- **Final completion:** 2019-07
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891837, "L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02891837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*